The main clinical application of
Thrombopoietin Receptor Agonist is as therapeutic agents of thrombocytopenia, especially thrombocytopenia caused by chemotherapy and radiotherapy.
Thrombopoietin Receptor Agonist in vivo experiments have shown that it not only increase platelet levels more effectively than other hematopoietic factors, but also has the ability to promote the viability of other hematopoietic cell lines. At the same time there are other studies confirm that Thrombopoietin Receptor Agonist not only stimulate growth megakaryocyte progenitor cells in vivo to increase its polyploidy, but also is effective in promoting bone marrow precursor cells Lin-Sca-1 + precursor activity, their offspring not only has the potential to generate megakaryocytes, also can be generated as bone marrow lines. Visiblely, Thrombopoietin Receptor Agonist will greatly reduce the risk of chemotherapy and bone marrow transplantation, effective treatment of thrombocytopenia and possibly other related disorders. Therefore Thrombopoietin Receptor Agonist will have broad application prospects.
Conbottpharm could give you:
1. Best quality in your requirement
2. Competitive price in China market
3. Mature Technical support
4. Professional logistic support
All we want is win-win business. Send yr. inquiries, you will get it!